MedTrace Logo

HIV - Monotherapy in Switzerland (MOST-ch)

NCT00531986 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-07-18

No results posted yet for this study

Summary

The investigators plan to conduct a two arm study, to compare failure rates in the central nervous system (CNS) and genital compartment in virologically fully suppressed patients continuing a highly active antiretroviral therapy (HAART) versus patients switching to ritonavir boosted lopinavir (Kaletra®) HIV-monotherapy. The study is composed of two phases of 48 weeks duration.

In addition, neuropsychological tests (Color trial test A 1 and 2; Grooved pegboard; EWIA Digit Symbol form) and evaluation of side effects will be performed.

Conditions

  • HIV Infections

Interventions

DRUG

Lopinavir-Monotherapy

Patients on triple HAART will be switched to LPV/r-monotherapy

DRUG

HAART

Patients will continued their current HAART

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • Swiss HIV Cohort Study

    collaborator NETWORK

  • Cantonal Hospital of St. Gallen

    lead OTHER

Principal Investigators

  • Pietro Vernazza, Professor · Swiss HIV Cohort Study

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2008-09-30
Completion
2008-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00531986 on ClinicalTrials.gov